Press release Lux phase 3 BIBW 2992 (afatinib)

Boehringer Ingelheim

New data on BIBW 2992*, a potent, irreversible, second-generation oral signal transduction inhibitor provides glimpse of next chapter in lung cancer care

Ingelheim/Germany, 06 September 2007

Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III pivotal trials in lung cancer with BIBW 2992*, its novel, second generation, potent, irreversibly binding, dual inhibitor of EGFR and HER2 and thereby further demonstrated its commitment to discovery and development of novel compounds in oncology. Details of this important stage in the clinical development of BIBW 2992* are currently being finalised with regulatory authorities in both the USA (FDA) and Europe (EMEA).

*BIBW 2992 is an investigational compound. Its safety and efficacy has not yet been fully established.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on